MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 592081 | Name: PCNA-I1
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

PCNA I1 is a proliferating cell nuclear antigen (PCNA) inhibitor. PCNA-I1 binds PCNA trimers (Kd = 0.41 μM), reduces chromatin-associated PCNA in cells. PCNA-I1 inhibits cell growth through induction of S and G2M arrest, and attenuates DNA replication in cells. PCNA-I1 Inhibits growth of a range of tumor cell lines in vitro with IC50 values in the nanomolar to low micromolar range. PCNA-I1 Inhibits growth of prostate tumor xenografts in mice.

Chemical Structure

PCNA-I1
PCNA-I1
CAS#444930-42-1

Theoretical Analysis

MedKoo Cat#: 592081

Name: PCNA-I1

CAS#: 444930-42-1

Chemical Formula: C17H14N2O2S

Exact Mass: 310.0776

Molecular Weight: 310.37

Elemental Analysis: C, 65.79; H, 4.55; N, 9.03; O, 10.31; S, 10.33

Price and Availability

Size Price Availability Quantity
25mg USD 350.00 2 Weeks
50mg USD 550.00 2 Weeks
100mg USD 950.00 2 Weeks
200mg USD 1,650.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
PCNA-I1; PCNAI1; PCNA I1;
IUPAC/Chemical Name
N'-[(1-hydroxy-2-naphthyl)methylene]-3-methyl-2-thiophenecarbo-hydrazide
InChi Key
NZWTWRNHYZNWNW-VCHYOVAHSA-N
InChi Code
InChI=1S/C17H14N2O2S/c1-11-8-9-22-16(11)17(21)19-18-10-13-7-6-12-4-2-3-5-14(12)15(13)20/h2-10,20H,1H3,(H,19,21)/b18-10+
SMILES Code
O=C(C1=C(C)C=CS1)N/N=C/C2=CC=C3C=CC=CC3=C2O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 310.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Dillehay KL, Seibel WL, Zhao D, Lu S, Dong Z. Target validation and structure-activity analysis of a series of novel PCNA inhibitors. Pharmacol Res Perspect. 2015 Mar;3(2):e00115. doi: 10.1002/prp2.115. Erratum in: Pharmacol Res Perspect. 2015 Aug;3(4):e00167. doi: 10.1002/prp2.167. PMID: 25729582; PMCID: PMC4324689. 2: Packard JE, Williams MR, Fromuth DP, Dembowski JA. Proliferating cell nuclear antigen inhibitors block distinct stages of herpes simplex virus infection. PLoS Pathog. 2023 Jul 24;19(7):e1011539. doi: 10.1371/journal.ppat.1011539. PMID: 37486931; PMCID: PMC10399828. 3: Dillehay KL, Lu S, Dong Z. Antitumor effects of a novel small molecule targeting PCNA chromatin association in prostate cancer. Mol Cancer Ther. 2014 Dec;13(12):2817-26. doi: 10.1158/1535-7163.MCT-14-0522. Epub 2014 Sep 24. PMID: 25253786. 4: Cheng H, Cao X, Min X, Zhang X, Kong Q, Mao Q, Li R, Xue B, Fang L, Liu L, Ding Z. Heat-Shock protein A12A is a novel PCNA-binding protein and promotes hepatocellular carcinoma growth. FEBS J. 2020 Dec;287(24):5464-5477. doi: 10.1111/febs.15276. Epub 2020 Mar 25. PMID: 32128976. 5: Zambalde ÉP, Pavan ICB, Mancini MCS, Severino MB, Scudero OB, Morelli AP, Amorim MR, Bispo-Dos-Santos K, Góis MM, Toledo-Teixeira DA, Parise PL, Mauad T, Dolhnikoff M, Saldiva PHN, Marques-Souza H, Proenca-Modena JL, Ventura AM, Simabuco FM. Characterization of the Interaction Between SARS-CoV-2 Membrane Protein (M) and Proliferating Cell Nuclear Antigen (PCNA) as a Potential Therapeutic Target. Front Cell Infect Microbiol. 2022 May 23;12:849017. doi: 10.3389/fcimb.2022.849017. PMID: 35677658; PMCID: PMC9168989. 6: Lengert AVH, Pereira LDNB, Cabral ERM, Gomes INF, Jesus LM, Gonçalves MFS, Rocha AOD, Tassinari TA, Silva LSD, Laus AC, Vidal DO, Pinto MT, Reis RM, Lopes LF. Potential New Therapeutic Approaches for Cisplatin-Resistant Testicular Germ Cell Tumors. Front Biosci (Landmark Ed). 2022 Aug 16;27(8):245. doi: 10.31083/j.fbl2708245. PMID: 36042160. 7: Lu S, Dong Z. Proliferating cell nuclear antigen directly interacts with androgen receptor and enhances androgen receptor‑mediated signaling. Int J Oncol. 2021 Jul;59(1):41. doi: 10.3892/ijo.2021.5221. Epub 2021 May 13. PMID: 33982774; PMCID: PMC8131087. 8: Tan Z, Wortman M, Dillehay KL, Seibel WL, Evelyn CR, Smith SJ, Malkas LH, Zheng Y, Lu S, Dong Z. Small-molecule targeting of proliferating cell nuclear antigen chromatin association inhibits tumor cell growth. Mol Pharmacol. 2012 Jun;81(6):811-9. doi: 10.1124/mol.112.077735. Epub 2012 Mar 7. PMID: 22399488; PMCID: PMC3362894.